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PRACTICAL APPLICATION
Sensitivity Analysis for Not-at-Random Missing Data
in Trial-Based Cost-Effectiveness Analysis: A Tutorial
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 The Author(s) 2018
Abstract Cost-effectiveness analyses (CEA) of ran-
domised controlled trials are a key source of information
for health care decision makers. Missing data are, however,
a common issue that can seriously undermine their validity.
A major concern is that the chance of data being missing
may be directly linked to the unobserved value itself
[missing not at random (MNAR)]. For example, patients
with poorer health may be less likely to complete quality-
of-life questionnaires. However, the extent to which this
occurs cannot be ascertained from the data at hand.
Guidelines recommend conducting sensitivity analyses to
assess the robustness of conclusions to plausible MNAR
assumptions, but this is rarely done in practice, possibly
because of a lack of practical guidance. This tutorial aims
to address this by presenting an accessible framework and
practical guidance for conducting sensitivity analysis for
MNAR data in trial-based CEA. We review some of the
methods for conducting sensitivity analysis, but focus on
one particularly accessible approach, where the data are
multiply-imputed and then modified to reflect plausible
MNAR scenarios. We illustrate the implementation of this
approach on a weight-loss trial, providing the software
code. We then explore further issues around its use in
practice.
Key Points for Decision Makers
Cost-effectiveness analysis of randomised trials with
missing data should assess the robustness of their
findings to possible departures from the missing at
random assumption.
Multiple imputation provides a flexible and
accessible framework to conduct these sensitivity
analyses.
Sensitivity analysis results should be reported in a
transparent way, allowing decision-makers to assess
the plausibility of their respective assumptions.
1 Introduction
Cost-effectiveness analyses (CEA) of randomised trials are
an important source of information to help decide which
health care programmes to provide. A common issue is that
there may be missing data, for example, because patients
withdrew from the trials or failed to respond to study
questionnaires, and this could result in biased findings and,
ultimately, wrong decisions being taken.
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There is now greater awareness that simple approaches,
such as discarding the participants with missing data, are
generally unsatisfactory [1–5]. The benefits of methods that
make use of all the available data and offer valid inference
under ‘missing at random’ (MAR) assumptions are now
well recognised, and recent years have seen an increase in
the use of such methods in CEA, in particular multiple
imputation (MI) [6, 7].
A key concern, however, is that conditional on the
observed data, the probability of cost-effectiveness data
being missing may still depend on the underlying unob-
served values, i.e. data may be ‘missing not at random’
(MNAR). For example, after adjusting for observed prog-
nostic factors, the chances of completing quality-of-life
questionnaires may depend on the patient’s (unobserved)
quality-of-life status. This raises particular challenges to
cost-effectiveness inferences because the analyst cannot
formally choose between MAR and MNAR given the data
at hand. Therefore, conducting sensitivity analyses to
assess whether conclusions are robust to plausible depar-
tures from MAR is widely recommended [1, 2, 8–10], and
these are particularly relevant for CEA which usually rely
on patient-reported outcomes. However, a recent review
has found that, in practice, cost-effectiveness studies rarely
conduct such a sensitivity analysis [7]. We discussed this
issue with stakeholders (academics from the University of
York and the London School of Hygiene and Tropical
Medicine analysing or reviewing cost-effectiveness evi-
dence for health care decision making), and an important
barrier that was identified was the lack of software tools
and guidance to conduct these analyses.
This tutorial paper aims to address this gap by present-
ing an accessible framework and practical guidance to
conduct sensitivity analysis for trial-based CEA with
missing data. This builds on previous guidance on missing
data in CEA [1, 3, 4], by focusing on sensitivity analysis
approaches to address MNAR. This paper introduces dif-
ferent approaches to MNAR analyses, but focuses partic-
ularly on the implementation of pattern-mixture models
using MI [11] as it was highlighted as the most accessible
and flexible approach during our discussions with stake-
holders. This tutorial assumes familiarity with the conduct
of MI (under the MAR assumption), which has been cov-
ered elsewhere [3, 4, 12, 13].
The remaining sections of this paper are organised as
follows. Section 2 provides a brief overview of the dif-
ferent approaches for MNAR analysis. Section 3 illustrates
a framework for MNAR sensitivity analysis, based on a
weight-loss trial, the Ten Top Tips (10TT) study. Section 4
discusses possible extensions to the proposed approach and
further considerations for implementing it in practice.
2 Overview of Missing Not at Random (MNAR)
Analysis Methods
2.1 Missing Data Mechanisms
The classification of the missing data mechanisms pro-
posed by Little and Rubin [14] provides a useful context.
Data are said to be missing ‘completely at random’
(MCAR), when missingness occurs for reasons unrelated to
the analysis question, and hence independent of the vari-
ables of interest. In this case, the observed data are repre-
sentative of the overall data and analysing the participants
with complete data will give valid results. A less restrictive
assumption is that the data are ‘missing at random’ (MAR),
so that the probability of a value being missing may be
dependent on observed data (e.g. intervention group, or
participants’ age), but—given the observed data—inde-
pendent of the underlying value itself. Finally, if, after
taking into account the observed variables, the chance of
observing the data is still associated with its value (for
example, if, after controlling for preceding data, a patient is
less likely to complete a health questionnaire when in
poorer health), the data are said to be ‘missing not at
random’ (MNAR, also called ‘informative’, or ‘non-ig-
norable’ missingness).
When missing data are MAR, valid conclusions can be
drawn from the data available using an appropriate
approach, such as MI [15]. MI has been widely recom-
mended as a flexible, practical approach to handle missing
data in CEA studies [1, 3–5, 12], and its uptake has been
steadily increasing [6, 7]. The idea of MI follows from
regression imputation (using the observed data to predict
the missing values), but appropriately takes into account
the uncertainty in the imputed values. To achieve this,
missing observations are replaced by plausible values
drawn from an appropriate predictive distribution of the
missing values given the observed data. To reflect the fact
that imputed values are estimated rather than known, and
hence uncertain, this process is repeated several times to
create several complete datasets. The analysis model is
then fitted to each ‘complete’ dataset, and the results are
combined for inference using Rubin’s MI rules [15], which
recognise the uncertainty both within imputations (sam-
pling uncertainty) and between imputations (uncertainty
due to missing data).
Analysis under MNAR is more challenging, as it implies
some relevant information is unobserved, and it requires
additional untestable assumptions to proceed with the
analysis. This naturally makes the MAR assumption the
typical starting point for the primary analysis of clinical
trials [16, 17]. However, because we cannot determine the
true missing data mechanism, sensitivity analyses should
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be conducted in order to assess whether conclusions are
robust to plausible departures from the MAR assumption
[1, 2, 8–10].
2.2 MNAR Modelling Frameworks
Various approaches have been proposed in the statistical
literature to conduct analysis under MNAR. These vary
according to how they formulate the MNAR model, how
they fit this model, and how the unobserved parameters are
informed and results reported as part of a sensitivity
analysis strategy. Here, we briefly review some of the main
MNAR modelling frameworks; for a more comprehensive
description, see Molenberghs et al. [11]. There are two
main ways to model possible departure from MAR:
selection models and pattern-mixture models.
Selection models specify the mechanism by which the
data are observed (or ‘selected’) as a function of the
underlying data values [15, 18]. For example, ‘for each
decrease of 0.1 in quality of life, the chance of being
missing doubles’ formulates the MNAR problem in
selection model terms. Selection models were commonly
used in early work on informative missing data; an
example in econometrics is Heckman’s selection model
[19], which is used to address selection bias. They have the
attractive feature that the missing data model can be
directly incorporated into the analysis model, for example,
using an inverse probability weighting approach [18, 20] or
numerical integration [21]. However, selection models
make untestable assumptions about the conditional distri-
bution of the unobserved data, and results can be very
sensitive to departure from these assumptions, as has been
shown elsewhere [14, 22–24]. This limitation is particu-
larly relevant for CEA studies, as the cost and effectiveness
endpoints tend to be difficult to parametrise. Another dis-
advantage is that selection models formulate sensitivity
analysis in a way that is not readily interpretable. For
example, a typical sensitivity parameter is the (log-)odds
ratio of how a unit change in the partially observed out-
come affects the chances of observing the data. This
specification makes the elicitation of such parameters
challenging, as well as the interpretation and communica-
tion of the sensitivity analysis results.
Pattern-mixture models, on the other hand, formulate
the MNAR problem in terms of the different distributions
between the missing and observed data. The overall dis-
tribution of a variable is seen as a mixture of the distri-
bution of the observed and the distribution of the missing
values (‘pattern-mixture’) [18, 25]. For example, ‘partici-
pants with missing data have a 0.1 lower quality of life than
those observed’ corresponds to a pattern-mixture formu-
lation. Pattern-mixture models have received increasing
attention over time [26], a key advantage being that they
rely on more easily interpretable parameters
[3, 18, 27–29]—such as the mean difference between
missing and observed data—and have therefore been
favoured in the context of clinical trial sensitivity analysis
[30, 31]. Different approaches can be used to formulate and
analyse pattern-mixture models, as we will see in the next
section.
Other forms of MNAR modelling have also been pro-
posed, but these can be seen as special cases of selection or
pattern-mixture models. In shared-parameter models, the
outcome and the missingness are linked through a latent
(unobserved) variable [32]. They have been particularly
used in the context of structural equation modelling.
Another approach which is gaining interest for use in
longitudinal trials is ‘reference-based’ or ‘controlled’
imputation, where missing data are assumed to follow a
distribution borrowed from another trial arm [33]. This
approach is yet to be explored in the CEA setting.
While any of the methods above would allow an
appropriate assessment of departures from MAR, we will
focus on the pattern-mixture approach in the remainder of
this paper because (1) it allows for more interpretable pa-
rameters, hence making this approach more accessible and
transparent; (2) it seems to be the main approach currently
used in clinical trial sensitivity analysis [7, 34]; (3) our
discussion with stakeholders confirmed this approach was
also appealing in the CEA context; and (4) pattern-mixture
models can be easily implemented using standard missing
data methods, such as MI, and build naturally on the MAR
analysis, as we will see below.
2.3 Sensitivity Analysis with Pattern-Mixture
Models
An approach for MNAR sensitivity analysis that has often
been suggested—under various forms—is to perform a
pattern-mixture model with a parameter capturing how the
distribution of the missing values Ymiss could differ from
the conditional distribution based on the observed data Yobs
[15, 18, 30, 35]. This can be done, for example, by using an
‘offset’ parameter d (delta) representing the average dif-
ference between the missing and observed values
(Ymiss ¼ Yobs þ dÞ: An alternative modification is to use a
multiplicative ‘scale’ parameter c, so that Ymiss ¼ Yobs  c.
For example, missing values could be assumed to be 10%
lower than those observed, or c ¼ 0:9. Figure 1 illustrates
an example of such modelling with a rescaling parameter.
In that example, a participant who drops out from the trial
is assumed to have on average a 10% lower quality of life
compared to a participant with similar characteristics who
remained in the trial. Note that this parameter is not derived
from the data, but is used to express one possible
assumption about the (unknown) missing data mechanism.
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Sensitivity analyses are then typically conducted over a
range of plausible values for this parameter, assessing how
different assumptions could result in different findings.
Several approaches can be used to inform the values of the
parameter in practice, and these are discussed further in
Sect. 4.3. We also discuss in Sect. 4.2 alternative
parametrisations that can be used to capture how missing
and observed data might differ.
Several approaches have been proposed to fit pattern-
mixture models, for example, within a Bayesian framework
[28, 36] or as an arithmetic function of the observed esti-
mates and using bootstrap or sandwich estimators to derive
the standard errors [18, 28]. But a particularly convenient
and flexible framework to fit these models is MI
[11, 15, 26, 37]. An approach commonly adopted in
practice consists of simply modifying multiply-imputed
data to reflect possible departures from the MAR
assumption [3, 7, 16, 38]. It involves the following steps:
1. Use MI to impute the missing values under an MAR
assumption.
2. Modify the MAR-imputed data to reflect a range of
plausible MNAR scenarios, for example, by multiply-
ing the imputed values by c, or by adding d:
3. Analyse the resulting dataset as one would a usual
multiply-imputed dataset, fitting the analysis model to
each imputed dataset and combining the results using
Rubin’s rules.
This approach is straightforward to implement in any
statistical software, and allows the effect of different
MNAR mechanisms on the conclusion to be easily asses-
sed, as we will illustrate in the next section.
3 Illustrative Application
3.1 The Ten Top Tips (10TT) Trial
3.1.1 Overview of the Trial and Cost-Effectiveness
Analysis
The 10TT trial was a two-arm, individually randomised,
controlled trial of a weight-loss intervention for obese
adults attending general practices in the UK [39]. The
intervention comprised self-help material delivered by a
practice nurse, providing the patients with a set of ten
simple weight-control behaviours, with strategies to make
them habitual. The participants randomised to the control
arm received care as usual from their general practices.
The primary trial outcome was weight loss at 3 months,
but participants were followed for 2 years to assess longer-
term outcomes and cost-effectiveness. Health-related
quality of life (HRQoL) was measured by EQ-5D-3L
questionnaires [40, 41] completed during study visits at
baseline and 3, 6, 12, 18 and 24 months, and quality-ad-
justed life years (QALYs) were derived by the ‘area under
the curve’, combining both time and utilities [10]. Total
costs were measured from the National Health Service
(NHS) perspective over the 2-year study period and based
on the intervention costs and the health resource use data
collected from the practice records at the end of the trial.
More details on the trial and CEA can be found in the
respective publications [39, 42, 43].
3.1.2 Missing Data
The trial recruited 537 participants, but only 313 (58%)
completed the last follow-up at 2 years. Missing data were
a major challenge for the CEA because only 31% of ran-
domised participants had complete HRQoL and cost data.
Missing data were mostly driven by missing EQ-5D data,
from participants who had either withdrawn from the trial
(76% of the missing HRQoL) or missed a follow-up
appointment (24%). Resource use data were derived from
the general practitioner records and were complete for 73%
of the participants (all the health care data were missing for
the remaining 27%). Details of the missing data by arm are
shown in Fig. 2. Although non-significant, missing data
appeared to be more common in the intervention arm (27
vs 34% of complete cases, p value = 0.075).
The primary CEA of the trial [43] was conducted under
the MAR assumption, using MI to impute the missing cost
and HRQoL values. It is, however, recognised in weight-
loss trials that participants who drop out could be those
with poorer outcomes [44]. This means that the chance of
Fig. 1 Example of pattern-mixture assumptions with rescaling.
Quality-of-life score over time for a trial participant, where missing
data are assumed to be 10% lower (c = 0.9) than would have been
imputed under a missing at random assumption. MAR missing at
random, MNAR missing not at random
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observing endpoints such as weight loss or HRQoL could
be dependent on their actual value, i.e. data are likely to be
MNAR. It is therefore important to assess the cost-effec-
tiveness results under different assumptions regarding the
missing data, including plausible MNAR mechanisms, as
we will illustrate in Sect. 3.2.
3.1.3 Cost-Effectiveness Analysis Methods
The CEA conducted in this tutorial follows the main
characteristics of the methods used for the trial’s primary
CEA [43], with some simplifications made to allow a clear
focus on the sensitivity analysis. Details of the analysis
variables are presented in Online Appendix 1 [see the
electronic supplementary material (ESM)]. Effectiveness
was measured in QALYs, and costs were captured by the
total health care use over the trial period (Sect. 3.1.1), as
derived for the primary analysis [43]. A discount rate of
3.5% per year was applied to both cost and effect.
Results are presented in terms of incremental cost,
incremental QALYs and incremental net monetary benefit
(INMB) at a cost-effectiveness threshold of £20,000 per
QALY. These were estimated alongside their 95% confi-
dence intervals (CIs) using non-adjusted linear regression,
comparing the 10TT arm to the control arm. Non-para-
metric bootstrap [45] was also used to produce the cost-
effectiveness plane [46], representing the uncertainty in
incremental cost and effect estimates, and the cost-
effectiveness acceptability curve (CEAC) [47], represent-
ing the probability of 10TT being cost-effective at different
thresholds. We focus on INMB rather than the incremental
cost-effectiveness ratio (ICER) as the intervention was
cost-saving. All the analyses were conducted in Stata
version 15 [48].
3.2 Sensitivity Analysis Example
In this section, we use the 10TT trial to illustrate MNAR
sensitivity analyses using a pattern-mixture approach fol-
lowing MI, as described at the end of Sect. 2.3.
3.2.1 MNAR Scenarios Explored
Several approaches can be used to decide on the relevant
MNAR scenarios for the sensitivity analyses, and this is
discussed further in Sect. 4.3. In this example, we con-
sidered that the missing HRQoL data may be MNAR,
while the MAR assumption is likely to hold for the
missing cost data (MNAR costs are discussed in
Sect. 4.1). It was postulated that patients who failed to
complete an EQ-5D questionnaire at a specific follow-up
assessment were likely to have been in relatively poorer
health (Sect. 3.1.2). More specifically, we assumed
patients’ HRQoL could be up to 10% lower (c = 0.9),
compared to the MAR setting (c = 1). This sensitivity
parameter c was allowed to differ by arm, with up to a
5% difference between the two arms (this reflects that the
missing data mechanism may not be the same in the two
arms, but that it is unlikely to be perfect MAR in one arm
and strong MNAR in the other). This resulted in seven
different MNAR scenarios, with c = 1.0, 0.95, or 0.9 for
either arm (Table 1).
3.2.2 Implementation of the Analysis in Stata
The annotated Stata code to conduct the analysis is pro-
vided in Online Appendix 2 (see the ESM), and the dataset
is described in Online Appendix 1.
Step 1. Performing Multiple Imputation
The first step of the analysis is to conduct standard MI
(under an MAR assumption), to ‘fill in’ the variables with
missing data. The missing HRQoL at each time point and
total costs were imputed stratified by arm, using a linear
model based on each other, and baseline characteristics
(age, sex, study centre, weight, body mass index and
baseline HRQoL). We conducted MI by chained equations,
using predictive-mean matching, and created 50 imputa-
tions. Note that alternative MI approaches, for example,
linear regression, would not affect the proposed sensitivity
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Fig. 2 Proportion of complete cost-effectiveness outcomes in 10TT
trial, by arm: QoL at each time point (3, 6, 12, 18, and 24 months),
overall QALY, and total cost. N = 270 in control arm and 267 in
intervention arm. QALY quality-adjusted life year, QoL quality of life,
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analysis strategy. More detailed guidance on conducting
MI in Stata is provided elsewhere [3, 13, 49].
Step 2. Modifying Imputed Data
To obtain the imputed data under MNAR, we simply need to
multiply each MAR-imputed value by c. For example:
replace qol_3=qol_3*0.9 if miss_qol_3==1 & arm==0 
will multiply the imputed values of qol_3 in the control
arm by 0.9.
Different versions of the modification could be imple-
mented at this stage (see Sect. 4.2), for example, by
alternatively considering an ‘offset’ additive parameter d:
replace qol_3=qol_3 + d if miss_qol_3==1 & arm==0 
This can be done in turn for each of the scenarios, or
storing each of the scenario parameters in a table (matrix)
allows Stata to execute this in one step, using a loop. The
modified data can then be saved in a single large dataset to
facilitate the remaining steps.
Step 3. Analysing the MNAR Dataset
The CEA analysis is then applied as usual to each of the
MNAR multiply-imputed datasets. To estimate the incre-
mental costs, QALYs and net monetary benefit and their
95% CIs, we have used the ‘mi estimate’ command, which
fits the analysis model on each of the imputed datasets,
then combines the results using Rubin’s rules [15]. We
have also used a non-parametric bootstrap approach to
produce the cost-effectiveness plane and the CEAC, with
the implementation described in Online Appendix 2 (see
the ESM). Further guidance on the analysis of multiply-
imputed cost-effectiveness data can be found elsewhere
[1, 3, 4, 12].
Step 4. Reporting
Clear reporting of the sensitivity analysis results is key to
ensure their implications are well understood. We recom-
mend a table which presents the summary findings for each
scenario (Table 1). Figure 3, which plots the cost-effec-
tiveness plane for the different MNAR scenarios is also
useful to understand the effect of each MNAR assumption,
as discussed in the next section. Our discussions with
stakeholders indicated that the most intuitive way to sum-
marise the findings was probably overlaying CEACs,
showing the probability of the intervention being cost-ef-
fective at different thresholds, for each MNAR scenario
(Fig. 4). Alternative presentations of the sensitivity analy-
sis results are discussed in Sect. 4.5.
3.2.3 Results
The 10TT CEA results under the different missing data
scenarios are reported in Table 1, Figs. 3 and 4. In par-
ticular, the CEAC (Fig. 4) shows that the probability of
10TT being cost-effective remains relatively stable when
Table 1 Cost-effectiveness of 10TT under different MNAR assumptions for missing quality-of-life data
Scenario
number
MNAR
rescaling
parametersa
Incremental costb (£) [95% CI] Incremental
QALYs [95% CI]
INMBc (£) [95% CI] Probability
cost-effectivec
(%)
ccontrol c10TT
1 (MAR) 1 1 - 35 [- 504 to 434] - 0.004 [- 0.074 to 0.066] - 49 [- 1632 to 1534] 48
2 1 0.95 - 35 [- 504 to 434] - 0.037 [- 0.107 to 0.032] - 713 [- 2280 to 853] 19
3 0.95 1 - 35 [- 504 to 434] 0.026 [- 0.044 to 0.095] 550 [- 1022 to 2121] 75
4 0.95 0.95 - 35 [- 504 to 434] -0.008 [- 0.076 to 0.061] - 115 [- 1670 to 1440] 44
5 0.95 0.90 - 35 [- 504 to 434] - 0.041 [- 0.109 to 0.027] - 780 [- 2321 to 762] 16
6 0.90 0.95 - 35 [- 504 to 434] 0.022 [- 0.046 to 0.091] 484 [- 1063 to 2030] 73
7 0.90 0.90 - 35 [- 504 to 434] - 0.011 [- 0.078 to 0.057] - 181 [- 1714 to 1352] 41
All results are based on imputed data and comparing the 10TT arm to the control arm (n = 537). For participants with complete cost and
effectiveness data (n = 166; 31%), the observed incremental cost was - £65 [95% CI - 924 to 794], incremental QALYs was - 0.040 [- 0.169
to 0.088], INMB was - £741 [- 3645 to 2163], and probability cost-effective was 31%
CI confidence interval, INMB incremental net monetary benefit, MAR missing at random, MNAR missing not at random, QALY quality-adjusted
life year, 10TT Ten Top Tips
aHow missing quality-of-life data are assumed to differ from the MAR-imputed values. ccontrol = 0.9 means that all imputed quality-of-life values
in the control arm have been reduced by 10%
bMissing costs assumed to be MAR in all scenarios
cAt a cost-effectiveness threshold of £20,000/QALY
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MAR departures are assumed to be the same across ran-
domised arms (scenarios 1, 4 and 7). This is also seen in
Table 1, where the alternative departures from MAR had
little effect on the incremental QALYs in these scenarios.
This will usually be the case when the missing data pattern
is broadly similar across treatment arms, as the MNAR bias
applies roughly equally to each arm and cancels out in the
treatment comparison.
As we move through the other scenarios, however, 10TT
alternates between being cost-effective and not depending
on which arm is assumed to have a stronger MNAR
mechanism. For example, 10TT appear unlikely to be cost-
effective when we assumed stronger MNAR (lower c) for
the treatment arm, with a probability of being cost-effec-
tive around 0.2 at £20,000 per QALY. Table 1 also shows
how the incremental QALYs vary across the different
scenarios, while the width of the 95% CI remains relatively
similar. Since the magnitude of the incremental QALYs
was relatively small, different missing data mechanisms
across arms led to substantially different incremental
QALYs estimates.
The impact of the different MNAR assumptions can also
be readily described in the cost-effectiveness plane
(Fig. 3). On the diagonal, where the MAR departures are
assumed to be the same in both arms, the joint distribution
of incremental QALYs and cost remains relatively
unchanged. However, differential changes of the sensitivity
parameter (c) between arms lead to a shift in the distribu-
tion of incremental QALYs to the right (10TT more cost-
effective) or left (10TT less cost-effective). These shifts
essentially reflect the impact of the MAR departures on the
incremental QALYs seen in Table 1. For example, for
scenarios where c is lower (stronger departure from MAR)
in the treatment arm (upper-right off-diagonal plots), the
joint distribution is shifted to the left and the proportion of
points below the cost-effectiveness threshold (£20,000 per
QALY) is lower (10TT less likely to be cost-effective).
4 Extensions
Section 3 provided a relatively simple example of a sen-
sitivity analysis. In this section, we discuss possible
extensions and further issues around their implementation
in practice.
4.1 Missing Cost
In our base-case example, we considered departures from
the MAR assumption for the effectiveness endpoint
(HRQoL) only. However, it is possible to consider MNAR
sensitivity analysis for the cost data as well, following a
similar approach.
Table 2 presents the results of a sensitivity analysis for
10TT when both the missing cost and HRQoL data were
considered to be MNAR. This involves four parameters,
capturing the MAR departure in total costs and HRQoL, in
each arm. The missing costs were assumed to be some-
where between MAR and up to 10% higher than observed
(i.e. participants who dropped out may have higher health
care use). Table 2 suggests that the departures from MAR
for the cost endpoint would only have a marginal effect on
the overall results, while departures for the HRQoL end-
point can strongly affect the conclusions, particularly if the
missing data mechanisms differ between arms. More
details on the analysis and the Stata code are provided in
Online Appendix 3 (see the ESM).
As the number of variables increase, so does the number
of sensitivity parameters, whose values we have to specify.
The number of plausible combinations of these parameters
can quickly become overwhelming, and it may be best to
focus on a limited number of scenarios, or on the param-
eters that affect the results the most, to allow for a mean-
ingful interpretation.
4.2 Alternative MNAR Parametrisation
In our example, we have rescaled the MAR-imputed
HRQoL by a multiplicative factor. As discussed in
Sect. 2.3, another popular pattern-mixture approach is to
‘offset’ the data by an additive factor. This is commonly
used for continuous outcomes measured on a readily
interpretable scale, such as EQ-5D, which is anchored at 0
(death) and 1 (full health). However, for cost data, a
multiplicative reduction may be more intuitive; for exam-
ple, a ‘10% reduction’ may be more readily understood
than a ‘£200 reduction’ as the latter is context specific. A
multiplicative transformation may therefore be more
appealing in the CEA context.
The values of the MNAR parameters could also be
varied according to other factors. With longitudinal data,
the departure from MAR can be assumed constant over
time—as was considered here—or changing over time, for
example, with the parameter increasing with time since
withdrawal [31, 37]. The parameter can also be applied at
different levels of data aggregation, for example, assuming
only one of the resource use components is likely to be
MNAR. Different parameters could also be used according
to the reasons for discontinuing the trial.
In principle, pattern-mixture models are very flexible
and the distribution of unobserved data could take any
shape or form. While it can be tempting to consider more
complex models (e.g. additional parameters), it can make
elicitation and interpretation challenging. In our view,
simple offsets or rescaling of the MAR distribution (al-
lowed to differ by arm) should usually provide sufficient
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span for a comprehensive sensitivity analysis, while
remaining sufficiently transparent.
4.3 Choosing the MNAR Parameters
One of the main concerns about conducting an MNAR
analysis is how to choose plausible sensitivity parameter
values. Several approaches and sources of information can
be used for this purpose. One potential approach is to
formally elicit ‘experts’ beliefs on the missing data distri-
bution [28]. These ‘experts’ can be anyone who can con-
tribute knowledge in understanding the missing data, such
as trial investigators, clinicians, or patients. Mason et al.
have developed a useful framework for eliciting expert
opinion about MNAR mechanisms in CEA [36]. The
experts’ beliefs, capturing the most likely value for the
MNAR parameters, and the uncertainty in that value, can
then be incorporated into the analysis model (see
Sect. 4.4).
Alternatively, one could simply use a ‘tipping point’ or
threshold analysis approach. This involves changing the
MNAR parameter until a different conclusion is reached
(for example, being or not being cost-effective). The ana-
lyst can then discuss with the relevant experts the plausi-
bility of this value. This approach is appealing because it is
more readily implemented and less time-consuming than
formal elicitation, and may provide sufficient information
for the decision problem at hand, especially when results
are robust to a wide range of assumptions. However, what
constitutes a ‘change of conclusion’ may not be uniquely
defined, and it may be difficult to implement with multiple
sensitivity parameters.
An intermediate approach would be to agree on plau-
sible sensitivity scenarios with those involved in the trial
or regulators, for example, at a steering committee
meeting. A ‘most likely’ scenario and several ‘most
extreme’ scenarios could be agreed on, without formally
eliciting the uncertainty in the parameters. The scenarios
should cover all plausible situations, so that readers can
be confident that missing data are unlikely to affect the
CEA conclusions beyond what is reported in the sensi-
tivity analysis.
Analysts should also consider how missing data are
addressed in the trial primary (clinical) analysis, and the
elicitation could be done jointly when suitable. The elici-
tation should ideally be conducted around the final stages
of data collection and be ‘pre-specified’ before the trial
results are known.
Overall, a clear understanding of the reasons for missing
data in the specific trial context, discussions with relevant
‘experts’, and insights drawn from the literature are key to
inform the choice of sensitivity parameters.
4.4 Probabilistic Parameters
An alternative to reporting results for specific sensitivity
parameters values is to incorporate the uncertainty around
the parameters into the analysis model. This is a natural
approach when a formal elicitation of the parameter’s value
and its uncertainty has been conducted (Sect. 4.3). While
the analysis can be conducted using a Bayesian framework
[36], it can also be implemented using MI [28, 37]. To do
so, instead of rescaling all the imputed dataset by a fixed
value, a random parameter value is drawn from the elicited
Table 2 Cost-effectiveness of 10TT under different MNAR assumptions for missing cost and effectiveness quality-of-life data
Scenario description Incremental cost
(£) [95% CI]
Incremental
QALYs [95% CI]
INMBa (£)
[95% CI]
Probability
cost-effectivea (%)
MAR - 35 [- 504 to 434] - 0.004 [- 0.074 to 0.066] - 49 [- 1632 to 1534] 48
Same MNAR parametersb in the two arms
- 10% QoL in both arms - 35 [- 504 to 434] - 0.011 [- 0.078 to 0.057] - 181 [- 1714 to 1352] 41
? 10% cost in both arms - 25 [- 512 to 462] - 0.004 [- 0.074 to 0.066] - 59 [- 1650 to 1532] 47
- 10% QoL and ? 10% cost - 25 [- 512 to 462] - 0.011 [- 0.078 to 0.057] - 191 [- 1733 to 1350] 40
Different MNAR parametersb in the two arms
- 10% QoL in intervention arm - 35 [- 504 to 434] - 0.071 [- 0.139 to - 0.002] - 1378 [- 2932 to 176] 4
- 10% QoL in control arm - 35 [- 504 to 434] 0.056 [- 0.014 to 0.125] 1148 [- 415 to 2711] 93
? 10% cost in intervention arm 20 [- 459 to 499] - 0.004 [- 0.074 to 0.066] - 104 [- 1691 to 1483] 45
? 10% cost in control arm - 80 [- 558 to 398] - 0.004 [- 0.074 to 0.066] - 4 [- 1591 to 1583] 50
All results are based on imputed data and comparing the 10TT arm to the control arm (n = 537)
CI confidence interval, INMB incremental net monetary benefit, MAR missing at random, MNAR missing not at random, QALY quality-adjusted
life year, QoL quality of life, 10TT Ten Top Tips
aAt a cost-effectiveness threshold of £20,000/QALY
bHow missing cost and QoL data are assumed to differ from MAR-imputed values
Sensitivity Analysis for Not-at-Random Missing Data
distribution for each of the imputed datasets. An example is
provided in Online Appendix 4 (see the ESM).
This probabilistic approach is particularly appealing as it
incorporates the uncertainty related to MNAR into the
analytical model, providing a ‘single’ answer. It can be
particularly relevant, for example, if the result is to be
incorporated in a larger decision model.
However, some stakeholders found this approach less
comprehensive than the reporting under different MNAR
scenarios. Indeed, this approach also relies on making a
single assumption (that the uncertainty was captured
appropriately), whereas a range of plausible scenarios may
be more readily interpretable in showing how different
missing data mechanisms could result in different
conclusions.
4.5 Presentation of Results
We have shown how to report the results for different
MNAR scenarios by displaying the resulting CEACs. This
was flagged by stakeholders as an accessible way to report
the results, but they have also recognised that alternative
graphical representations may be preferred depending on
the decision problem at hand. In this section, we illustrate
some of these graphical tools (Stata code provided in
Online Appendix 5; see the ESM).
For example, Fig. 5 shows the INMB (and CIs) for
values of the c parameter, ranging from 0.8 to 1. The
parameter is applied to both arms simultaneously, or only
one of the arms.
Alternatively, a more comprehensive description of
possible combinations of the sensitivity parameters across
treatment arms is plotted in Fig. 6. This ‘colour-coded
graph’ (or contour plot) provides a useful tool to interpret
the implications of different departures from MAR on the
overall decision. For example, it illustrates that for lower
values of c (stronger departure from MAR) in the inter-
vention arm compared to the control group, the 10TT
intervention is unlikely to be cost-effective (red/orange
area).
5 Discussion
In this tutorial, we have outlined different approaches for
conducting sensitivity analysis for missing data in CEA.
We focused on one particularly accessible approach, based
on pattern-mixture modelling with MI, and illustrated how
it can be implemented in practice. While this is not, in any
sense, the final word, we believe that more widespread use
of the approach described here would represent a sub-
stantial step towards realising the regulatory call for sen-
sitivity analysis.
As Sect. 2 highlights, numerous approaches to MNAR
analyses are possible, and there is a large literature on this
topic [11, 18, 37]. However, we believe the approach
illustrated here has the key advantages of accessibility,
flexibility, and transparency. Transparency is indeed the
principal requirement for these sensitivity analyses to serve
their purpose, as the plausibility of their underlying
assumptions needs to be clearly understood and critically
assessed by a broad readership [2, 16, 31]. The straight-
forward implementation of the analysis within an MI
framework makes it accessible to the increasing number of
analysts who are routinely using MI. It can also be readily
implemented within any statistical software with MI (Stata,
R, SAS, SPSS, etc.).
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Fig. 5 Alternative presentation: incremental net monetary benefit of
10TT compared to control arm (at £20,000/QALY), for different
values of the MNAR rescaling parameter. CI confidence interval,
MAR missing at random, MNAR missing not at random, QoL quality
of life, 10TT Ten Top Tips
Fig. 6 Alternative presentation: contour plot of the probability of
10TT being more cost-effective than control (at £20,000/QALY), for
different values of MNAR rescaling parameters in the control and
intervention arms. MAR missing at random, MNAR missing not at
random, QALY quality-adjusted life year, QoL quality of life, 10TT
Ten Top Tips
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Ready implementation allows the focus to be on iden-
tifying relevant MNAR scenarios and assessing their
plausibility. We discussed here several approaches that can
be used in practice, whose suitability will depend on each
situation. Some approaches are more rigorous, but more
time-consuming, while others are cruder, but still infor-
mative. Deciding on the relevant scenarios is likely to
involve discussion with other collaborators, and the ana-
lysts should be able to explain the different assumptions in
non-technical language. Another challenge is the reporting
of the results: how can the analyst ensure that the sensi-
tivity analysis is comprehensive, without being over-
whelming for the readers? We have suggested a framework
where the analysis is conducted under a limited number of
plausible scenarios, and the results reported in a table and
on a combined CEAC, but also discussed alternative
presentations.
The proposed framework is not without some limita-
tions, however. First, every trial raises different issues, and
it is not possible to recommend a universal framework for
MNAR sensitivity analyses. The framework suggested here
is nevertheless relatively flexible, and should be suitable in
a wide range of settings, including longitudinal and cluster-
randomised trials. Secondly, an assumption such as ‘the
missing HRQoL are 10% lower’ could be too simplistic to
capture the varied reasons behind missing data. However, it
is important to consider this in light of several aspects. We
are primarily interested here, as is usually the case in
randomised trials, in estimating mean differences between
groups. To obtain valid conclusions, it is therefore not
necessary to predict accurately each missing value, but
only the average difference between observed and missing
data. Also, the true missing data mechanism is always
unknown, and the aim of the sensitivity analysis is not to
provide a definitive answer, but to indicate how conclu-
sions could differ under different missing data assump-
tions. Finally, the framework proposed here was for
continuous outcomes such as cost and quality of life. While
the main ideas of the framework are relevant for other
outcomes (e.g. binary or survival), they do raise additional
challenges, especially around model compatibility and
elicitation [37]. For example, differences between observed
and missing data in terms of ‘odds ratios’ may be more
difficult to elicit and interpret.
While this tutorial focuses on within-trial CEA, a similar
sensitivity analysis approach could possibly be used in
observational settings, for example, when analysing rou-
tinely collected data, where the issue of informative
missing data may arguably be even more important.
This tutorial highlights several areas where further
research could improve the value of CEA for decision
making in the presence of missing data. A particularly
interesting alternative MNAR approach is ‘reference-
based’ or ‘controlled’ imputation, where the missing data
are assumed to follow a distribution that is ‘borrowed’
from another group. For example, in a trial comparing a
drug to placebo, it could be assumed that patients dropping
out from the experimental arm have stopped taking their
treatment, and therefore follow a similar pattern to that
seen in the control arm [33]. This approach is appealing as
it sidesteps the elicitation of quantitative parameters
required for selection or pattern-mixture models, and
instead formulates the MNAR assumption in a qualitative
way. It was well received when discussed with stakehold-
ers, but, to our knowledge, has not yet been used in the
CEA context. Relevant areas for further research also
include incorporating the sensitivity analysis results into
broader decision models and, related to this, conducting
sensitivity analysis without patient-level data. One possi-
bility could be to approximate the MNAR bias based on the
proportion of missing data, and to retain the analysis
standard errors as a measure of sampling uncertainty.
Further guidance on how to best address missing binary
and survival endpoints is still needed. While we propose
some routes for eliciting sensitivity parameters, this critical
aspect deserves further attention, and is likely to evolve as
MNAR analyses become more routinely performed.
In summary, CEA based on incomplete data should
routinely assess whether the study’s conclusions are robust
to potential departures from the standard MAR assumption.
This paper described some approaches to conducting these
sensitivity analyses, and illustrated the application of a
practical, accessible framework using pattern-mixture
models with MI. This approach builds on the increasing use
of MI in CEA and should provide an important step
towards improving practice in trial-based CEA.
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